Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era

In a review of 14 studies, central nervous system (CNS) relapse ranged from 2.3% to 10% in non-Hodgkin lymphoma (NHL) patients (excluding acute lymphoblastic leukaemia/lymphoma (ALL/LBL) and Burkitt lymphoma (BL)) with an overall risk of CNS relapse of 4.7%.1 Indolent lymphomas such as follicular lymphoma and mantle cell lymphoma do not spread to the brain as frequently as the high grade lymphomas such as ALL/LBL and BL (2.8% and 24.4%, respectively).2

Source: Clinical Lymphoma, Myeloma and Leukemia - June 7, 2016 Category: Hematology Authors: Megan M. Herr, Nimish A. Mohile, Paul M. Barr, Edwin van Wijngaarden, Edward B. Brown, David Q. Rich Tags: Case Report Source Type: research